Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
44.5M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
5.94M
-
Shares change
-
-1.15M
-
Total reported value, excl. options
-
$9.5M
-
Value change
-
-$1.3M
-
Number of buys
-
34
-
Number of sells
-
-33
-
Price
-
$1.60
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share (OTLK) as of Q2 2025
82 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2025.
Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share (OTLK) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.94M shares
of 44.5M outstanding shares and own 13.35% of the company stock.
Largest 10 shareholders include Schonfeld Strategic Advisors LLC (1.36M shares), VANGUARD GROUP INC (1.25M shares), MORGAN STANLEY (426K shares), Steward Partners Investment Advisory, LLC (366K shares), BlackRock, Inc. (340K shares), MILLENNIUM MANAGEMENT LLC (339K shares), GEODE CAPITAL MANAGEMENT, LLC (266K shares), FMR LLC (171K shares), Squarepoint Ops LLC (156K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (118K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.